Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FS120 Alone and in Combination With Pembrolizumab in Advanced Malignancies
NCT04648202Phase 1Terminated
- Sponsor
- invoX Pharma
- Start
- Nov 2020
- Primary completion
- Jan 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of FS120 in cancer, sponsored by invoX Pharma. Primary endpoints: Incidence, severity, and duration of adverse events (AEs), serious adverse events (SAEs) and dose limiting toxicities (DLTs) at 24 months and Determination of a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) at 24 months. Started Nov 2020; status: terminated.
02
Drugs
FS120
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04648202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04648202.